Health
UK Scientists Uncover Breakthrough in Asthma and COPD Treatment
A new treatment approach for asthma and chronic obstructive pulmonary disease (COPD) has been identified by scientists in the UK, marking what is being hailed as the first major advancement in managing these conditions in half a century.
The findings, published in The Lancet Respiratory Medicine, reveal that a single injection of benralizumab, a monoclonal antibody, is significantly more effective than traditional steroid tablets in reducing symptom flare-ups, known as eosinophilic exacerbations. These episodes account for roughly 50% of asthma attacks and 30% of COPD attacks, causing symptoms such as wheezing, coughing, and chest tightness.
A New Approach to Inflammation
Steroid tablets, the conventional treatment, work by reducing inflammation in the lungs but are not effective for all patients and can lead to serious long-term side effects like high blood pressure and osteoporosis. In contrast, benralizumab targets white blood cells to reduce lung inflammation, curbing symptoms and lowering the need for additional treatments by 30%, according to the study.
“This could be a game-changer for people with asthma and COPD,” said Dr. Mona Bafadhel, lead investigator and chair of respiratory medicine at King’s College London.
Widespread Impact
COPD affects an estimated 36.6 million Europeans, while nearly 10 million people under 45 have asthma. These conditions significantly impact patients’ quality of life, particularly older individuals with both diseases, who often face limited life expectancies.
“We need to provide these patients with life-saving options before their time runs out,” said Dr. Sanjay Ramakrishnan, a study author and clinical senior lecturer at the University of Western Australia. He criticized current treatments as being “stuck in the 20th century.”
Trial Highlights
The study divided high-risk asthma and COPD patients into three groups: one received benralizumab, another steroids, and the third both treatments.
After 28 days, those treated with benralizumab showed better respiratory outcomes. At the 90-day mark, 74% of steroid-treated patients required further medical intervention due to treatment failure, compared to only 45% of those who received the antibody injection.
The findings suggest that a single benralizumab injection could become a vital emergency treatment, reducing hospital readmissions for asthma and COPD patients.
A Pivotal Moment in Respiratory Care
“We hope these pivotal studies will change how asthma and COPD exacerbations are treated for the future, ultimately improving the health for over a billion people living with asthma and COPD across the world,” Bafadhel stated.
The trial, supported by AstraZeneca and the University of Oxford, offers renewed hope for better management of respiratory diseases, potentially transforming care for millions globally.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
